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ABSTRACT Loss of heterozygosity (LOH) on the short
arm of chromosome 17 (17p) was found in 27 of 52 (52%)
previously untreated primary breast cancers. There was a
significant correlation between this 17p allelic loss and two
parameters associated with aggressive tumor behavior: high
cellular proliferative fraction and DNA aneuploidy. These
correlations with high cellular proliferative fraction and DNA
aneuploidy were not found in tumors with LOH at nine other
chromosome locations. The p53 gene, a putative tumor sup-
pressor gene located at 17p13, was examined for aberrations to
determine whether it is the target for the 17p LOH in breast
cancer. Unlike other types of human cancer, there were no
homozygous deletions or rearrangements of the p53 gene, and
only 2 of 13 (15%) were mutated in the conserved region where
mutational "hot spots" have been previously located. There-
fore, we hypothesize that, in breast cancer, either loss or
inactivation of gene(s) on chromosome 17p other than the p53
gene or a different mechanism of p53 gene inactivation may be
responsible for the observed high labeling index and DNA
aneuploidy associated with LOH at 17p.
Loss of heterozygosity (LOH) at chromosomal locations
associated with tumor suppressor genes has recently been
implicated in the genesis of many forms of human malignan-
cies (1, 2). LOH at chromosome 17p has been reported in
various human cancers, including colorectal carcinomas (3),
lung cancers (4), and glioblastomas (5), and in neurofibro-
matosis (6). In breast cancers, 50-60% of cases have allelic
losses at this region (7-10). To date, correlations have not
been reported between LOH at 17p and various clinicopatho-
logical parameters of breast cancers, including nodal status,
presence of hormone receptors, tumor stage, and histology
(9, 10).
The p53 gene, a 53-kDa nuclear phosphoprotein (11), has
been assigned to chromosome region 17p13 (12). Several
studies have indicated that the wild-type p53 gene product
functions as a tumor suppressor (13, 14). In experimental
systems as well as in human tumors, various mechanisms
resulting in loss of the normal p53 gene function have been
implicated in tumorigenesis. Observed aberrations of p53
include genomic rearrangement (15), homozygous deletions
(15, 16), and LOH with concomitant point mutations in a
highly conserved region of the remaining p53 allele (3, 17).
Here we confirm the observation (7, 8) that LOH on the
short arm ofchromosome 17 is a frequent allelic loss in breast
cancers. We found that this loss correlated with high bro-
modeoxyuridine (BrdUrd) labeling index and DNA aneu-
ploidy, characteristics of aggressive tumor behavior in vivo
(for review, see ref. 18). However, mutations of the p53 gene
were rarely detected in these breast cancers and the few
cancers showing mutations did not correlate with the 17p
LOH or high labeling index. Therefore, the linkage between
LOH at 17p and certain parameters of aggressive disease
appears to be independent of DNA aberrations in the con-
served region of the p53 gene.
MATERIALS AND METHODS
Human Tissue Samples and Cultured Cells. Human breast
tumor samples and skin biopsies were removed surgically.
Tumor samples were dissected to remove most of the normal
tissue. All samples were stored in liquid nitrogen until use.
Whenever the skin tissues were too small to isolate sufficient
DNA for analysis, cultured skin fibroblasts from the same
patient were used to extract DNA.
DNA Isolation and Southern Blot Analysis. High molecular
weight DNA was isolated from cultured fibroblasts, pulver-
ized skin biopsies, and breast tumors as described (19).
Restriction endonuclease digestion ofDNA samples, agarose
gel electrophoresis, Southern transfer, prehybridization, hy-
bridization to DNA probes 32P-labeled by random priming
technique (Amersham) (20), and autoradiography were per-
formed as described (21). Quantification of the hybridization
signals was performed with a Molecular Dynamics (Sunny-
vale, CA) laser scanning densitometer. A reduction of >30%
of the normal signal (as adjusted with the signals obtained
from normal tissue) was recorded as an allelic loss. All but 3
of the 27 cases with LOH at 17p had a reduction in signal
intensity >50%. DNA probe pYNZ22 was kindly provided by
Y. Nakamura (Howard Hughes Medical Institute, Salt Lake
City). p53 cDNA probe was kindly provided by A. J. Levin
(Princeton University).
BrdUrd Labeling and Detection. BrdUrd was given to patients
intravenously in normal saline at 200 mg/M2 over 30 min just
prior to tumor excision. Slices 1 mm thick were fixed in 70%o
ethanol and embedded in paraffin. Alternately, in vitro labeling
as described by Meyer and McDivitt (22) was used if in vivo
labeling was not available. A 1-mm-thick tumor slice was
incubated in RPMI medium containing 10 ,uM 5-fluorodeoxyu-
ridine (Sigma) and 100 ,uM BrdUrd (Sigma) under hyperbaric
oxygen for 2 hr at 37°C. Tumors were fixed in 70%o EtOH before
embedding. Incorporated BrdUrd was detected immunologi-
Abbreviations: LOH, loss of heterozygosity; PCR, polymerase chain
reaction; VNTR, variable number tandem repeat.
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cally with IU4 antibody (Lawrence Livermore National Lab-
oratory) after denaturing DNA in 2 M HCI. For formalin-fixed
tissue, crosslinked proteins were cleaved by protease treatment
prior to denaturation. The Elite ABC kit for routine indirect
immunoperoxidase staining was used to detect incorporated
BrdUrd. Light counterstaining with hematoxylin allowed de-
tection of BrdUrd-negative nuclei. Calculation of the BrdUrd
labeling index (the number ofpositively stained cells divided by
the total number of cells counted) was done by scoring a
minimum of 2000 cells in multiple well-labeled, high-power
fields.
DNA Flow Cytometry. DNA content was measured by the
detergent/trypsin protocol of Vindelov et al. (23). Fresh
samples were finely minced to create single cell suspensions
and treated with buffers containing detergent and trypsin to
produce nuclear suspensions without excess debris. Nuclei
were stained with propidium iodide (10 gg/ml) and analyzed
for total DNA content using the FACScan flow cytometer
(Beckton Dickinson). Normal lymphocytes were used as an
internal control to define diploidDNA content when a diploid
population was not present in the tumor sample. Chicken
erythrocytes were used as a second internal control. DNA
index was calculated as the modal channel number for tumor
cell DNA content divided by the modal channel number for
normal cells. Diploid was defined as having a DNA index of
1.0 ± 0.05, and aneuploid was defined as having a second
nondiploid peak that was separable from the diploid popu-
lations.
Fluorescence in Situ Hybridization. A single cell suspension
of tumor cells was fixed in Carnoy's fixative and dropped
onto precleaned microscope slides. Cells were hybridized
overnight with biotinylated probes specific for pericentro-
meric sequences on chromosomes 1, 7, and 17 as described
(24). The number of hybridization signals for each chromo-
some was counted in >400 interphase cells.
Polymerase Chain Reaction (PCR). PCR (25) was per-
formed with 200-400 ng of genomic DNA under standard
conditions using Amplitaq DNA polymerase (Perkin-Elmer/
Cetus). At least two, and in some cases three or four,
amplification reactions were performed for each DNA sam-
ple. Primer sequences were taken from the published coding
and intron sequences for p53 (26). A 2.9-kilobase (kb) ge-
nomic DNA fragment containing exons 4-9 was amplified
using a 0.5 ,uM final concentration of primers GACGGAAT-
TCGTCCCAAGCAATGGATGAT and GTCAGTCGACCT-
TAGTACCTGAAGGGTGA. The amplified 2.9-kb product
was electrophoresed on a 0.8% agarose gel, stained with
ethidium bromide, and recovered using the "Geneclean"
procedure as recommended by the manufacturer (Bio 101,
LaJolla, CA). Five to 10%6 of the yield was subjected to a
second "asymmetric" PCR (27) using 0.01 ,uM primers for
exon 5 (TTCCTCTTCCTGCAGTACT and AGCTGCTCAC-
CATCGCTAT), for exon 7 (TGTTGTCTCCTAGGTTGGCT
and CAAGTGGCTCCTGACCTGGA), or for exon 8
(CCTATCCTGAGTAGTGGTAA and TCCTGCTTGCT-
TACCTCGCT). The concentrations ofthe PCR primers were
0.5 ,uM and 0.01 AM, respectively. Both strands were se-
quenced for each exon. The respective primers were then
used in the sequencing reactions.
Sequencing Reaction. The product of the asymmetric PCR
was purified and dissolved in 15 ,u of water; 7.5 ,l of this was
taken for each sequencing reaction. Sequencing was per-
formed by the modification ofthe method ofSanger et al. (28)
as optimized for United States Biochemical Sequence. The
reaction mixture was then electrophoresed on an 8% poly-
acrylamide 5 M urea gel for 2 hr with 55 W and exposed to
X-Omat AR film (Kodak) overnight.
Data Base Storage and Retrieval. The breast cancer data
base is maintained in the Informix relational data base
management system (Informix, Belmont, CA), running under
Ultrix on a Microvax II computer (DEC, Waltham, MA).
Demographic, clinical, and research data from clinical
sources and several laboratories are stored in tables in the
data base, and the data are linked by patient accession
numbers. Data are retrieved using the data base query
language SQL (structured query language) or using GQL
(graphical query language; Andyne Computing, Ontario,
Canada), a Macintosh computer-based program that commu-
nicates with the data base and allows access to data using
simpler, graphical methods.
RESULTS
Correlation of Pathobiological Parameters with Aflelic Loss
on Chromosome 17p. Seventy-eight primary breast carcino-
mas were analyzed for allelic loss on the short arm of
chromosome 17 using a variable number tandem repeat
(VNTR) probe, pYNZ22, located at 17p13.3. Fifty-two ofthe
cases were heterozygous at this locus and so were informa-
tive. Twenty-seven of the 52 informative cases (52%) dem-
onstrated LOH at this locus. Examples of allelic loss at
chromosome 17p are illustrated in Fig. 1.
To determine whether those cases with LOH at 17p13.3
constituted a biologically distinct subset of breast cancers,
the clinical and biological properties ofthose cases with LOH
were compared with the properties of those cases that were
informative but had no loss. A marked difference in BrdUrd
labeling index was detected between the two groups (Fig. 2).
Among the tumors that retained heterozygosity at 17p, most
had low labeling indices. In contrast, many of the cases with
LOH at 17p had a labeling index >5%. This difference
between the two types of tumors was statistically significant
using the Mann-Whitney rank test (P = 0.0065; additional
statistical tests described below).
There was only one case with a labeling index >10% that
did not show LOH at 17p by Southern analysis (*, Fig. 2).
However, an existing LOH may not be detected if it occurs
in some but not all tumor cells, and/or if there is substantial
contamination ofthe tumor tissue with nonmalignant cells. In
this study, a signal reduction of at least 30%o was required to
define LOH. To further characterize the tumor with high
S-phase fraction but no LOH (*, Fig. 2), additional studies
were undertaken using fluorescence in situ hybridization with
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FIG. 1. LOH at loci on chromosome 17p in breast tumors. DNA
samples from normal skin tissue (lanes N) and tumors (lanes T) were
obtained from patients B172, B202, and B208. The DNAs were
digested with Taq I and hybridized to 32P-labeled pYNZ22 probe.
The allelic designations (al, a2) are indicated on the left of the
autoradiogram. c, Constant band.
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FIG. 2. Correlation between LOH at 17p13.3 and S-phase frac-
tion of primary breast cancer. LOH at 17p13.3 was defined using
pYNZ22 probe by Southern blot analysis. S-phase fraction (%) was
obtained by BrdUrd labeling. Each circle represents a case of breast
cancer. The asterisk (*) represents the single case where LOH was
absent by Southern blot analysis but was shown to be 40%o mono-
somic for chromosome 17 using in situ hybridization with a peri-
centrimeric probe on chromosome 17.
somes 1 and 7 were predominantly disomic, 40% of the
interphase cells in the same preparation were monosomic for
chromosome 17 (Table 1). It is likely that the p arm is also
monosomic in cells with centromeric monosomy; therefore,
40% monosomy together with some normal cell contamina-
tion could readily explain the scoring of this case as infor-
mative with no LOH at 17p.
To determine whether the correlation between LOH at 17p
and high S-phase fraction was specific for LOH at 17p, data
were collected on LOH at nine other loci: 1p, lq, 2q, 4p, 11p,
11q, 17p, 18p, and X. For each locus, the samples were
divided into two classes: those with and those without LOH,
and the frequency of cases with S-phase fraction 25% was
determined. Because the various probes differed in degree of
polymorphism, LOH was not equally ascertainable at all
chromosomal loci. Only for chromosomes lq and 17p were
there sufficient data for statistical testing. As an additional
comparison with results for 17p, the data of LOH at all
chromosomes except 17p were pooled.
The association between allelic loss and high S-phase
fraction and five other markers associated with poor prog-
nosis are summarized in Table 2. The number of informative
cases and the fraction of total cases with S phase -5% for
samples with and without LOH are indicated (see "S-phase
fraction .5%"). The odds ratio (29) was calculated at 7.5,
indicating that when LOH at 17p is present, it is 7.5 times
more likely that the S-phase fraction will be .-5% than when
LOH at 17p is absent. The precision of this statistic is
Table 1. Distribution of chromosome copy number per cell
Signals, Chromosome, %
no. per cell No. 1 No. 7 No. 17
0 2 0.3 0.8
1 11.3 1.9 40.6
2 76.6 89.2 54.6
3 9.96 7.0 2.8
4 0 0 1.2
Total n 291 315 249
indicated by the 95% confidence interval whose lower bound-
ary was >1, indicating that it is highly likely that S-phase
fraction .5% and LOH at 17p are related.
Statistical significance also was evaluated based on x2 test
formed by the 2 x 2 table relating LOH to S-phase fraction
-5%. One-sided tests were used because it was expected, a
priori, that LOH would represent a deviation from normality
and thus be associated with markers of poorer prognosis.
One-sided P values for the x2 evaluation are indicated in
Table 2.
The data in Fig. 2 and Table 2 indicate that there is a
significant correlation between high S-phase fraction and
LOH that is specific for 17p. When either the pooled data
minus LOH at 17p or LOH at another individual locus, lq,
are examined, there is no longer a significant correlation with
high S-phase fraction.
A similar statistical evaluation with performed for the five
other pathobiological indicators of poor patient prognosis. As
with high S-phase fraction, there was a very strong correla-
tion between loss at 17p and aneuploid DNA content (odds
ratio, 15.4; one-sided P value, 0.0016). However, there was
no correlation between aneuploidy and LOH at the other loci
examined. LOH at any ofthe chromosomal loci tested did not
significantly correlate with positive axillary nodes, advanced
T stage, hormone receptor status, age of the patient, or
histological type of breast cancer (data not shown).
Genetic Aberrations of the p53 Gene Occurs Infrequently in
Primary Breast Cancers. A potential target of the LOH at 17p
in breast cancer is the p53 gene, located at chromosome
17pl3.1. To determine whether the p53 gene is the target for
LOH at 17p in breast cancer, we analyzed the tumor DNA for
evidence of homozygous deletions, rearrangements, or mu-
tations of the p53 gene. DNA from 50 breast cancers was
digested with EcoRI and examined by Southern blot analysis
using a p53 gene cDNA probe, pc53-SN. There was no
evidence for either homozygous deletions or abnormally
migrating bands indicative of gene rearrangements.
Eight breast cancers with allelic loss at 17p (including five
with high S-phase fraction) and five cases that were infor-
mative with no loss were selected for further analysis.
Genomic DNA from these cases was used to sequence an
evolutionarily conserved region of the p53 gene that includes
exons 5, 7, and 8 where mutations of the p53 gene have been
detected in other tumors (17, 26). A 2.9-kb DNA fragment for
sequencing was generated by PCR. Only two mutations were
detected in all 13 DNA samples examined. One was from a
case with allelic loss at 17p and high S-phase fraction; four
other similar cases were negative. The mutation, located at
codon 149, was specific for the tumor since it was not found
in DNA from skin fibroblasts of the same patient (Fig. 3).
Mutations were not detected in three additional cases with
LOH at 17p13.3 but with low proliferative index. The other
tumor with a p53 mutation at codon 175 was one of the five
cases examined with a low S-phase fraction that retained
heterozygosity at 17p (data not shown).
For 9 of 11 cases without p53 mutations, LOH was
detected in one or more chromosomal loci. Therefore, these
DNA preparations were predominantly derived from tumor
cells. Since the same DNA samples were used for p53
sequence analysis, any p53 mutations in the tumor DNA
would have been detected. For these studies, the sensitivity
of detecting p53 mutations was such that 1 mutant allele in 10
would have been detected (30). Thus, only if a mutant allele
was present in <10% of the DNA, would it have been missed
in this analysis. The above analyses show that the correla-
tions ofLOH at 17p with high S-phase fraction and with DNA
aneuploidy cannot be explained by mutations or other genetic
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Table 2. Association between pathobiological markers and allelic loss for primary breast cancer
95% confidence interval
for odds ratio
Chromosome Odds Lower Upper One-sided
Marker locus Informative No LOH LOH ratio boundary boundary P value*
S-phase fraction -5% 17p 43 3/18 15/25 7.50 1.72 32.80 0.0049
Any except 17 69 20/45 12/24 1.25 0.46 3.37 0.33
1q 47 16/31 5/16 0.43 0.12 1.52 0.09
DNA aneuploid 17p 32 5/16 14/16 15.40 2.49 95.06 0.0016
Any except 17 59 18/36 16/23 2.29 0.76 6.88 0.069
lq 42 12/27 10/15 2.50 0.67 9.31 0.084
*Based on x2 distribution.
DISCUSSION
We have demonstrated that allelic loss on chromosome 17p
correlates with high labeling index and DNA aneuploidy.
These biological correlations are specific for LOH at chro-
mosome 17p since significant correlations were not observed
in breast cancers with LOH at other analyzed chromosomal
locations. Even though our studies utilized only probes on
the short arm ofchromosome 17, others (8) demonstrated that
the q arm was rarely involved in tumors with LOH on
chromosome 17p. Therefore, we hypothesize that loss of
function for a gene(s) located on chromosome 17p results in
a phenotype characterized by DNA aneuploidy and rapid
cellular proliferation.
Several studies have indicated that the wild-type p53 protein
functions as a tumor suppressor and that inactivation of the
p53 gene results in malignant transformation (13, 14). Inacti-
vation of the p53 gene may be accomplished by deletion,
rearrangement, and/or mutation; all of these have been found
with high frequency in the p53 gene of primary colon carci-
nomas (3, 17), lung carcinomas (15, 17), glioblastomas (17),
sarcomas (16), and neurofibromatosis (6). Mutations of p53
have also been- found in human breast cancer cell lines (31).
Because of its involvement in so many other human
malignancies and breast cancer cell lines, it has been pro-
posed that the p53 gene, which is located at chromosome
region 17p13, is the target for the 17p LOH in primary breast
cancer. However, none of 50 cases analyzed had a homozy-
gous deletion or gene rearrangement and only 2 of 13 cases
(15%) had mutations in the conserved region of the p53 gene




FI*.3. Mutation in breast carcinoma specimen as detected by
direct PCR sequencing. (a) Specimen 187, the wild-type sequence of
the p53 gene within the fifth exon using skin fibroblast DNA. (b)
Specimen 187, a C -.+ T mutation at codon 149 changing a Pro to a
Ser in the breast carcinoma DNA. The wild-type sequence is still
present in this tumor due to contaminating normal DNA. The
sequence is read from a 5' --) 3' direction starting from the top to the
base of the gel. The arrowhead indicates the site of C --+ T mutation
in the primary breast carcinoma DNA.
even though -50% of breast cancers had LOH at chromo-
some 17p. Of the two primary breast cancers with mutated
p53, one had a high S-phase fraction and LOH at 17p,
whereas the other was heterozygous at 17pl3.3 and had a
very low S-phase fraction. Thus we conclude that neither
mutations in the conserved region nor deletions in the re-
maining allele of the p53 gene are responsible for the patho-
biological properties associated with 17p LOH in breast
cancers. Although a mutated p53 gene does occur in a small
proportion of primary breast cancers, the role of these
mutations remains to be elucidated.
In breast cancer, in vitro immortalization has been asso-
ciated with late stages of malignant progression (32). There-
fore, the high incidence of p53 mutations seen in breast
cancer cell lines relative to primary breast cancer suggests
that mutation of the p53 gene may be a late event in breast
cancer malignant progression. Similar observations have
been made for another oncogene, ras. Activating ras muta-
tions have been detected in a high proportion ofcolon (33, 34)
and lung (35) cancers and in breast cancer cell lines but not
in uncultured primary or metastatic breast cancers (36).
These observations suggest that various types of human
cancers may differ in the sequence of acquiring genetic
aberrations or in the specific genes involved.
Our results suggest that inactivation of a gene on chromo-
some 17p other than p53 may be responsible for conferring a
high S-phase fraction and DNA aneuploidy in primary breast
cancers. There is precedence for the hypothesis that two
suppressor genes may be located on the same chromosome
arm. For example, two loci on the short arm of chromosome
11 (11p13 and ilp15) have been implicated in the develop-
ment of Wilm tumor and hepatocellular carcinomas (37).
Furthermore, Coles et al. (38) recently identified two distinct
regions of loss ofheterozygosity on chromosome 17p, located
in bands p13.3 and p13.1. An alternate explanation consistent
with the results is that the 17p loss occurs in conjunction with
loss at another, as yet unidentified, region where the gene in
question is actually located. Whichever explanation proves
correct, a deletion-mapping study using a panel of polymor-
phic markers to define the smallest common region of dele-
tion will be helpful in identifying the region on chromosome
17p associated with high S-phase fraction and DNA aneu-
ploidy in breast cancer.
In summary, we have shown that LOH of 17p is signifi-
cantly associated with high S-phase fraction and DNA ane-
uploidy, indicators of aggressive tumor behavior. However,
LOH was not associated with mutation of the p53 tumor
suppressor gene. These results suggest that the 17pl3 region
contains gene(s) whose function is important in the suppres-
sion of breast cancer and that this activity may involve
another gene besides p53. Alternately, if p53 is the target
gene, its inactivation must occur by a mechanism other than
mutation of the conserved region where mutational "hot
spots" have been previously located.
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